<DOC>
	<DOC>NCT00607152</DOC>
	<brief_summary>Primary: To compare the efficacy of Rasburicase versus allopurinol in controlling tumor lysis-related hyperuricemia in Chinese patients with leukemia or lymphoma. Secondary: To compare the efficacy and safety of Rasburicase versus allopurinol in Chinese patients stratified according to disease (leukemia or lymphoma ).</brief_summary>
	<brief_title>Rasburicase (Fasturtec) Registration Trial</brief_title>
	<detailed_description />
	<mesh_term>Hyperuricemia</mesh_term>
	<mesh_term>Allopurinol</mesh_term>
	<mesh_term>Rasburicase</mesh_term>
	<criteria>At high risk of malignancy and/or chemotherapyinduced hyperuricemia Performance status less than 3 on ECOG scale or more than 30% KPS scale Uric acid concentrations â‰¥ 8.0mg/dL Suffering from nonHodgkin's lymphoma Stage more than III, or acute lymphoblastic leukemia with peripheral with blood cell count more than 25,000/mm3, or any lymphoma or leukemia Treatment with an investigational drug at any time during the 14day study period (except for agents that are permitted by the Sponsor) Pregnancy or lactation Prior treatment with Uricozyme or Rasburicase Scheduled to receive asparaginase either 24 hours after the first dose of rasburicase Treatment with Allopurinol within the seven days preceding study Day 1 History of significant atopic allergy problems or documented history of asthma History of severe reaction to allopurinol Known history of glucose6phosphate dehydrogenase deficiency. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>